ARYx Therapeutics, Inc.
ARYX · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Market Cap | $13 | $14 | $26 | $89 |
| - Cash | $3 | $1 | $6 | $7 |
| + Debt | $12 | $8 | $9 | $12 |
| Enterprise Value | $23 | $20 | $29 | $93 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$3 | -$6 | -$5 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$4 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.075 | -0.11 | -0.22 | -0.21 |
| % Growth | 31.7% | 50% | -4.8% | – |
| Operating Cash Flow | -$4 | -$4 | -$6 | -$6 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$4 | -$4 | -$6 | -$6 |